Less for Less: CVS drops Zepbound for Wegovy

CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).

If GLP1 is so great, why don't people stick with it?

Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.

A glowing endorsement of GLP1s by cardiologists

Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.

A new risk? Macular Degeneration

We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.

Updates from MariTide & Orforglipron research

MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.

After two months, Novo Nordisk and HIMS part ways

Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.

Preserving muscle: GLP1s with Bimagrumab

We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.

Novo Nordisk patent protections lapse in Canada

Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.

A challenge to Eli Lilly's Tirzepatide patent

Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.

Amylin, with and without GLP1: Eloralinitide

We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.

Ozempic is not likely to directly enlarge the male appendage.

A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.

Eli Lilly's big Summer 2025 update

We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.

research

Semaglutide vs Tirzepatide (Clinical trial)

Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.

company:roche

Roche and Carmot's GLP1 pipeline

We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.

category:news

A new risk: Kidney Cancer

New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.

malady:addiction

GLP1s vs. Addiction, a quick review

We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.

drug:retatrutide

An update on Retatrutide (May 2025)

We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.

category:benefits

GLP1s lower inflammation, Psoriasis, AND increase fertility?

We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.

politics

GLP1s and Tariffs, the story so far

We take a look at the various movements in GLP1 policy by the Trump administration, so far.

drug:wegovy

Wegovy in pill form is coming

Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.

drug:nimacimab

Boosting Tirzepatide with Nimacimab

Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.

company:eli-lilly

Eli Lilly suing GLP1 compounders & related companies

Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.

company:pfizer

Pfizer ends development of oral GLP1 Danuglipron

Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.

drug:mounjaro

Mounjaro's India launch

Eli Lilly's Mounjaro launches in India